Improved Radiation Therapy of Hypoxic Tumor Regions by Integrated PET, EPR, and MR Imaging - Resubmission 01 - Revision - 1

通过集成 PET、EPR 和 MR 成像改进缺氧肿瘤区域的放射治疗 - 重新提交 01 - 修订版 - 1

• 批准号: 10289582
• 负责人: Chin-Tu Chen
• 金额: $ 40.34万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-01-01 至 2024-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10289582
• 关键词: APP-PS1; Administrative Supplement; Algorithms; Alzheimer' s Disease; Alzheimer' s disease brain; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; Amyloid beta-Protein; Blood - brain barrier anatomy; Brain; Brain Hypoxia; Brain region; Cerebral Hypoxia; Chemicals; Chicago; Clinical; Deposition; Detection; Development; Disease; Disease Progression; Doctor of Philosophy; Electron Spin Resonance Spectroscopy; Encapsulated; Evaluation; Exclusion; Funding; Gold; Grant; Health; Human; Hypoxia; Image; Imaging Device; Intervention; Label; Location; Magnetic Resonance Imaging; Malignant Neoplasms; Measures; Methodology; Methods; Misonidazole; Modality; Monitor; Multimodal Imaging; Mus; NIH Program Announcements; Nanotubes; Parents; Pathologic; Patients; Perfusion; Positron-Emission Tomography; Process; Publishing; Radiation therapy; Research; Research Project Grants; Resistance; Route; Senile Plaques; Silicon Dioxide; Therapeutic Effect; Tissues; Tracer; Translating; United States National Institutes of Health; Universities; Work; brain tissue; cerebral oxygenation; clinical imaging; contrast enhanced; human subject; imaging approach; imaging modality; improved; interest; molecular imaging; mouse model; new technology; novel; preclinical imaging; radioresistant; response; sensor; tissue oxygenation; tumor; tumor hypoxia

Abstract A number of hypoxic processes have been pathologically correlated with the development of amyloid plaque in Alzheimers's disease (AD). Nonetheless the local development of amyloid-b plaque (Ab) has not been successfully correlated with local brain hypoxia. We argue that the importance of registration of hypoxic loci in the brain with location of the development of Ab will enable the precise evaluation of the response of clinical intervention to mitigate hypoxic loci in the mitigation of the AD process. Our funded research grant R01 CA236385, as outlined in its abstract above, is to improve PET hypoxia imaging using 18F-Misonidazole (FMISO) in localizing radiation resistant hypoxic tumor regions incorporating two clinically available MRI modalities: dynamic contrast enhanced MRI (DCE-MRI) and Iopamidol chemical exchange saturation transfer MRI (ICEST-MRI). The gold standard for the detection of tumor regions with low pO2, i.e., hypoxic, is electron paramagnetic resonance pO2 imaging (EPRpO2 imaging). This supplement availability announcement NOT- AD-20-034 as part of the general supplement fundung opportunity announcement PA-18-591 provides a unique opportunity for expanding the application of imaging local hypoxia from cancer resistance to a second, quite distinct and generally crucial health problem: Alzeheimer's Disease (AD). The development of a preclinical imaging methodology to screen interventions that modulate local cerebral hypoxia may provide breakthrough information that will inform the mitigation of AD. We propose to use a novel technology to inject via an intraparenchymal route mesoporous silica nanotubes (MSNs) encapsulating the quantitative EPRpO2 sensor which we recently published to image local pO2. This will overcome the blood brain barrier exclusion of the triacid EPRpO2 sensor. The work will use 18F labeled NAV4694 to locate Aβ in the brain of both C57BL/6 control and APP/PS1 AD mouse models. We will correlate the location of this biomarker of AD with locations of low pO2 in the mouse brain. Additional PET images of the distribution of the hypoxia marker FMISO and DCE- MRI for measuring perfusion and ICEST-MRI for assessing tissue pH will be obtained. The MRIs will be used to correct the FMISO PET images to better agree with the EPRpO2 image, leading to a novel algorithm for using clinical imaging approaches of FMISO PET and DCE-MRI and CEST-MRI methods in human subjects to locate hypoxia in the brains of AD and related dementia patients and determine if mitigation of this hypoxia can mitigate the AD process.

抽象的 许多缺氧过程与淀粉样斑块的形成在病理学上相关。 然而，阿尔茨海默病 (AD) 的局部发展尚未得到证实。 我们认为记录缺氧位点的重要性。 具有抗体发育位置的大脑将能够精确评估临床反应 在缓解 AD 过程中减轻缺氧位点的干预措施。 CA236385，如上面摘要中所述，旨在使用 18F-米索硝唑改善 PET 缺氧成像 (FMISO) 结合两种临床可用的 MRI 定位抗辐射缺氧肿瘤区域 方式：动态对比增强 MRI (DCE-MRI) 和碘帕醇化学交换饱和度转移 MRI (ICET-MRI) 检测低 pO2（即缺氧）肿瘤区域的黄金标准是电子。 顺磁共振 pO2 成像（EPRpO2 成像）。 AD-20-034 作为一般补充资助机会公告的一部分 PA-18-591 提供了 将局部缺氧成像的应用从抗癌扩展到第二个的独特机会， 非常独特且普遍重要的健康问题：阿尔茨海默病（AD）。 筛选调节局部脑缺氧干预措施的临床前成像方法可能会提供 我们建议使用一种新技术来注射，为缓解 AD 提供突破性信息。 通过实质内途径介孔二氧化硅纳米管 (MSN) 封装定量 EPRpO2 我们最近发布了用于对局部 pO2 进行成像的传感器，这将克服血脑屏障的排斥。 这项工作将使用 18F 标记的 NAV4694 来定位 C57BL/6 大脑中的 Aβ。 我们将 AD 生物标志物的位置与 APP/PS1 AD 小鼠模型的位置相关联。 小鼠大脑中低 pO2 的缺氧标记 FMISO 和 DCE- 分布的附加 PET 图像。 将使用 MRI 测量灌注和 ICEST-MRI 评估组织 pH 值。 校正 FMISO PET 图像，使其与 EPRpO2 图像更好地一致，从而产生了一种新颖的算法 在人类受试者中使用 FMISO PET 和 DCE-MRI 和 CEST-MRI 方法的临床成像方法 定位 AD 和相关痴呆症患者大脑中的缺氧情况，并确定缓解缺氧是否可以 减轻 AD 过程。